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Systemic immune activation, a major determinant of HIV disease progression, is the 
result of a complex interplay between viral replication, dysregulation of the immune 
system, and microbial translocation due to gut mucosal damage. While human 
genetic variants influencing HIV viral load have been identified, it is unknown to 
what extent the host genetic background contributes to inter-individual differences 
in other determinants of HIV pathogenesis like gut damage and microbial 
translocation. Using samples and data from 717 untreated participants in the Swiss 
HIV Cohort Study and a genome-wide association study design, we searched for 
human genetic determinants of plasma levels of intestinal fatty-acid binding protein 
(I-FABP/FABP2), a marker of gut damage, and of soluble sCD14 (sCD14), a marker 
of LPS bioactivity and microbial translocation. We also assessed the correlations 
between HIV viral load, sCD14 and I-FABP. While we found no genome-wide 
significant determinant of the tested plasma markers, we observed strong 
associations between sCD14 and both HIV viral load and I-FABP, shedding new light 
on the relationships between processes that drive progression of untreated HIV 
infection. 
 

















HIV infection is characterized by systemic immune activation, which persists even 
with viral suppression by antiretroviral therapy, and this immune activation is 
associated with HIV pathogenesis and disease progression in treated and untreated 
individuals [1, 2]. One cause of immune activation is microbial translocation, which 
occurs when microbial products from the lumen of the gastrointestinal (GI) tract 
translocate into the systemic circulation through a damaged GI tract barrier [3]. 
Immune activation and gut damage are cyclically linked, with immune activation 
leading to damage of the structural and immune barriers of the GI tract, and 
translocated microbial products stimulating the systemic immune system. This 
interplay is complex, and multiple factors affect each aspect of this vicious cycle, 
with the virus initiating and driving the process in the absence of treatment.   
Soluble CD14 (sCD14) is a biomarker found at the heart of this interaction. Because 
it is a secreted sensor of bacterial lipopolysaccharide (LPS), sCD14 acts as an 
indirect marker of microbial translocation. The plasma levels of sCD14 were 
associated with mortality in two studies of HIV-infected individuals who were on 
antiretroviral therapy [4, 5]. Intestinal fatty-acid binding protein (I-FABP encoded 
by FABP2) is a marker of GI tract enterocyte damage [6], and thereby makes it 
possible to indirectly measure structural damage to the GI tract, which would be 
prohibitive to sample in a large cohort. The plasma levels of I-FABP also showed 
some association with mortality in treated HIV populations and were inversely 















correlated with CD4+ T cell counts [4, 5]. These plasma markers allow the large-
scale measurement of GI tract damage and microbial translocation. 
Human genetic variation is known to play a modulating role in the host response to 
HIV infection. Multiple genome-wide association studies (GWAS) have been 
performed in cohorts with HIV control phenotypes, primarily in individuals of 
European ancestry, and mostly focusing on HIV viral load or disease progression 
(CD4+ T cell decline or time to AIDS) [7-10]. These studies consistently identified a 
small number of genetic variants associated with viral control, including single 
nucleotide polymorphisms (SNPs) mapping to the HLA class I region on 
chromosome 6, and a 32 base pairs deletion in the CCR5 gene (CCR5Δ32) on 
chromosome 3. On the other hand, there is no reported GWAS of GI tract damage or 
microbial translocation, so it is unknown to what extent these essential aspects of 
HIV pathogenesis are influenced by host genetic variation, and whether they also 
correlate with the HLA-B, HLA-C and CCR5 variants associated with viral load. Of 
note, early candidate gene studies reported the existence of SNPs affecting sCD14 
and I-FABP plasma levels, but these associations have yet to be confirmed in HIV 
populations and in larger cohorts. The minor allele of rs2569190, a SNP mapping to 
the CD14 promoter region, was associated with higher plasma levels of sCD14 [11]. 
The same SNP was associated with significant differences in secretion of sCD14 and 
IL-6 in LPS-stimulated PBMCs [12]. Two haplotypes have also been identified in the 
FABP2 promoter (built from rs1799883, rs10034579, rs2282688 and rs6857641) 
that associated with I-FABP expression differences in vitro [13, 14]. 















To better understand how genetic factors may impact the interrelated processes of 
viral replication, gut damage and microbial translocation leading to systemic 
immune activation, we measured the plasma levels of sCD14 and I-FABP in 717 
untreated, clinically and genetically well-characterized HIV-infected subjects from 
the Swiss HIV Cohort Study (SHCS), and used a GWAS design to search for human 
genetic variants associated with these biomarkers. We did not identify any 
significant genetic associations with sCD14 or I-FABP plasma levels, and found that 
the human genetic variants that are known to associate with HIV viremia do not 
associate with sCD14 or I-FABP levels. On the other hand, we observed independent 
associations between sCD14 and both HIV viral load and I-FABP, demonstrating the 
intricate relationships that exist between the various pathogenic mechanisms 





The study subjects are part of the Swiss HIV Cohort Study (SHCS), a nationwide 
cohort study with continuous enrollment and semiannual study visits (www.shcs.ch 
[15]). The SHCS has been approved by the Ethics Committees of all participating 
institutions. Each study participant provided written informed consent for genetic 
testing. HIV infected individuals were eligible if they had [1] genome-wide 
genotyping data generated in the context of a previous GWAS; [2] a stored plasma 















sample that was collected between 3 and 6 years after estimated date of 
seroconversion, in the absence of antiretroviral treatment, and with a CD4+ T cell 
count of at least 350/μl of blood; and [3] at least 3 stable plasma HIV RNA results, 
obtained in the absence of antiretroviral treatment, at least 6 months after the 
known or presumed date of infection, and with a CD4+ T cell count of at least 350/μl 
of blood. Set point viral load was calculated as the mean of all log10 transformed 
viral results fitting these conditions. 
 
Plasma biomarker measurements 
I-FABP and sCD14 plasma levels were measured as previously described using 
commercially available ELISAs [5]. The I-FABP assay (Cell Sciences) was performed 
on plasma diluted to 50%, and the sCD14 assay (R&D Systems) was performed on 
plasma diluted to 0.5%. All analyses were performed blinded to clinical and genetic 
status. Each test was determined in duplicate, and the average value of each marker 
was calculated and used in the downstream analyses. 
 
Genotyping and imputation 
Genotyping was performed using the Illumina HumanHap550 array, as described 
previously [8]. After quality control of the genotyping data and exclusion of 
population outliers by principal component analysis (PCA) [16], 686 individuals 
with complete phenotype and genotype data were available for downstream 
analysis. Genotypes were imputed using the 1000 Genomes Project CEU reference 















panel: we used mach1 for prephasing [17] and minimac for imputation [18]. 
Imputed SNPs with a minor allele frequency of at least 1% and an imputation 
quality score (r2) of at least 0.3 were kept for association testing. The CCR5Δ32 
variant, which is not represented directly or indirectly on the genome-wide chip, 
was independently genotyped with a TaqMan assay. 
 
Association testing 
We use GWAPower for power calculation [19]. Association tests were carried out by 
linear regression using plink [20], and by linear mixed model regression using 
fastlmm [21]. The fastlmm kernel matrix was computed from 69k randomly selected 
SNPs (corresponding to 1% of the total number of tested SNPs). Regressions were 
performed against log10 normalized HIV viral load at set point, log10 normalized 
sCD14 plasma levels and log10 normalized I-FABP plasma levels. Age, sex and the 
coordinates of the top 3 PCA axes were included as covariates in all regression 
models. We used Bonferroni correction for multiple testing. Association statistics 
between sCD14, FABP2, viral load at set point and the SNPs were computed by 
linear regression using R.  
 
















Common human genetic variants are not associated with markers of GI tract 
damage or microbial translocation 
We analyzed HIV infected patients that had been genotyped in the context of a 
previous GWAS [8]. A total of 6,982,014 SNPs, directly genotyped on Illumina arrays 
or imputed using the 1000 Genomes Project CEU population as reference, were 
available for association testing. Stored plasma samples were obtained from eligible 
treatment-naïve subjects, and the plasma levels of I-FABP and sCD14 were 
measured by ELISA. A total of 717 participants had complete genetic and phenotypic 
data, of which 31 were identified as population outliers by principal component 
analysis of the genotyping data and excluded. Therefore the final study population 
consisted in 686 individuals of European ancestry. Demographic and laboratory 
information for all study participants is shown in Table 1. 
No associations were found between any human SNP and the plasma levels of I-
FABP or sCD14 during early chronic, untreated HIV infection, after correction for 
multiple testing (Figure 1). Our study was powered to detect genetic variants that 
explain at least 4% of the variability in sCD14 or I-FABP plasma levels.  
We also specifically looked at the SNPs that were previously reported as associated 
with sCD14 and I-FABP plasma levels. We did not observe any association between 
sCD14 plasma levels and the CD14 promoter SNP rs2569190 (p=0.46), and between 
I-FABP plasma levels and the FABP2 promoter SNPs rs1799883, rs10034579, 
rs2282688 and rs6857641, alone or in haplotype combinations (all p>0.3). 
















I-FABP plasma levels and HIV viral load are associated with sCD14 plasma 
levels 
We next examined the correlations between several factors known to play a role in 
HIV pathogenesis: HIV viral load at set point, CD4+ T cell count, plasma level of 
sCD14 and plasma level of I-FABP. CD4+ T cell count was not associated with sCD14 
or I-FABP plasma levels (p>0.5 and r2<0.01 for both), and this parameter was 
excluded from subsequent analyses. Of note, the distribution of CD4+ T cell counts 
was truncated due to the inclusion criterion that all study participants have CD4+ T 
cell counts > 350 cells/ul; the median value was 452 in the study population 
(interquartile range: 390-566).  
We observed a moderate correlation between plasma levels of I-FABP and sCD14 
(p=7.1x10-16, r2=0.09, Figure 2a), confirming the obvious link between GI tract 
damage and microbial translocation. This correlation was largely independent of 
HIV viral load (p=3.5x10-15 when viral load was included as covariate in the 
regression model).  
HIV plasma viral load at set point was strongly associated with sCD14 but not with I-
FABP plasma levels (p=7.1x10-8 and p=0.2 respectively, Figure 2 b,c). The strong 
association observed between viral load and sCD14 plasma levels during chronic 
untreated infection is consistent with a cyclical relationship between HIV replication 
and immune activation due to microbial translocation. On the other hand, the 
absence of correlation between viral load and I-FABP concentration suggests that 















the virus is not a major driver of GI tract damage during the chronic phase of 
infection. This finding is consistent with the fact that this marker of enterocyte 
damage can still be detected in individuals on suppressive antiretroviral therapy [2].  
 
Human genetic variants associated with HIV control are not associated with 
sCD14 or I-FABP plasma levels 
Three genetic variants have been consistently shown to associate with HIV control 
in previous GWAS: rs2395029, a near-perfect proxy for HLA-B*57:01 in Europeans; 
rs9264942, an indirect marker of HLA-C expression levels; and the CCR5Δ32 
deletion in its heterozygous form. We tested them for association with viral load at 
set point in linear regression models that included sex, age, and the coordinate of 
the top 3 principal component axes as covariates. The associations were again 
significant for all 3 variants in our study population (Table 2). However, there was 
no association with sCD14 or I-FABP plasma levels (all p-values > 0.05).  
To further explore the potential interactions between HIV viral load at set point, 
host genetic variants and sCD14 plasma levels, we ran multivariate regressions on 
viral load, including the 3 genetic variants as independent variables, with or without 
sCD14 plasma levels in the model: rs2395029, rs9264942 and CCR5Δ32 remained 
significant predictors of viral load and the strength of the association did not change 
significantly when the regressions included sCD14 plasma levels (Table 2). Thus, 
the previously described genetic variants in the HLA-B, HLA-C and CCR5 regions and 



















HIV pathogenesis is the result of a complex interaction between the virus and the 
host response, which results in immune dysregulation. Many factors have been 
identified that independently contribute to pathogenesis but their intricate 
relationships have yet to be fully elucidated. In particular, host genetic factors and 
systemic immune activation due to the translocation of microbial products from the 
gut have both been shown to have a strong impact on HIV control and disease 
progression, but these have not been studied in relation to each other. We therefore 
sought to measure plasma markers of GI tract damage and microbial translocation 
in clinically and genetically well-characterized patients from the SHCS.  
We ran a GWAS searching for human genetic determinants of sCD14 or I-FABP 
plasma levels, and failed to identify significantly associated variants after correction 
for multiple testing. As our study was powered to detect variants that explain at 
least 4% of sCD14 or I-FABP variability, we conclude that the plasma levels of these 
biomarkers are not primarily determined by common genetic variants with 
moderate to high effect size.  
We did not observe any association between a previously reported CD14 promoter 
variant and sCD14 plasma levels, which strongly suggests that in untreated HIV-
infected individuals, this biomarker primarily reflects LPS bioactivity/microbial 















translocation rather than underlying genotype, in keeping with the demonstrated 
strength of this measurement as a predictive biomarker of disease progression. Of 
note, in the original report [11], homozygosity for the rs2569190 minor allele only 
associated with a 0.04 log10-transformed sCD14 increase, whereas the range of 
log10-transformed sCD14 values was 5.9-6.6 (delta: 0.7) in our study population. 
Similarly, we did not identify any association between FABP2 genotypic variation 
[13, 14] and plasma levels of I-FABP, which suggests that enterocyte damage, rather 
than genetically-determined expression differences in I-FABP, drives the plasma 
level of I-FABP in HIV-infected patients.  
We then searched for associations between sCD14 and I-FABP plasma levels and the 
degree of spontaneous HIV control (as reflected in viral load) during the chronic 
phase of HIV infection, and found that sCD14 strongly associates with both I-FABP 
and viral load. Much of the work that has been previously done on sCD14 and I-
FABP has focused on treated HIV infection, as gut damage, microbial translocation 
and systemic inflammation are the focus of current therapeutic efforts to decrease 
the non-AIDS morbidity and premature mortality observed in patients with 
suppressed viremia on antiretroviral therapy. In a cohort of mostly treated HIV 
infected individuals, Sandler et al. found a large increase in the risk of death with 
higher plasma sCD14, and an inverse association between plasma I-FABP level and 
CD4+ T cell counts [5]. A recent study by Hunt et al. found a significant correlation 
between I-FABP and sCD14 in treated subjects with advanced disease, and each 
marker strongly predicted mortality independently of CD4+ T cell count [4]. In fact, 















a similar correlation between gut damage and LPS-induced monocyte activation has 
also been observed in HIV-negative subjects [22].  
To date, only one study has examined the predictive value of sCD14 for mortality in 
untreated chronic HIV infection [23]: sCD14 was correlated with both viral load and 
CD4+ T cell count, and the association of sCD14 with disease progression was not 
independent of these parameters. Our data add to this important area of research by 
also including a marker of enterocyte damage, and by testing the relationships 
between all these parameters in a larger, genetically homogeneous group of 
untreated individuals. 
Our observation that I-FABP is associated with sCD14 but not with viral load during 
chronic untreated infection suggests that, although the virus itself begins and 
reinforces the vicious cycle of enterocyte damage, translocation of microbial 
products and immune activation, these processes may become largely independent 
of viral replication in the chronic phase of untreated infection. This would be 
consistent with the high levels of immune activation that can still be observed in 
some individuals under fully suppressive antiretroviral therapy [2]. The interaction 
between these measures is likely to be bidirectional, as enterocyte damage allows 
microbial translocation and sCD14 increase due to LPS-induced monocyte 
activation, while chronic immune activation is likely to further damage the GI tract 
barrier.  Interestingly, this correlation between I-FABP and sCD14 plasma levels was 
not observed in primary HIV infection, suggesting that microbial translocation is not 
the primary driver of monocyte activation during the acute phase of infection [24].  















The strong association that we found between sCD14 and viral load, which had 
already been described in a small group of untreated patients [5], is most likely 
indirect. The presence in plasma of microbial products, including LPS, leads not only 
to higher sCD14 levels, but also to systemic inflammation, which is known to 
increase HIV viral load [25].  
When considering the negative results of our genetic scan, specific limitations of the 
study design need to be highlighted. Some variability in sCD14 and I-FABP 
measurements was inevitable, which probably had a negative impact on study 
power. Each sample was tested in duplicate to deal with potential assay variability, 
but due to the lack of suitable samples we did not repeat the measurements at 
different time points, which would have allowed a precise estimation of biological 
variability. Another potential confounder is the variable duration of HIV infection (3 
to 6 years) before sampling, potentially leading to inter-individual differences in 
disease progression. The exclusion of patients with moderate to severe 
immunosuppression (CD4+ T cells <350) aimed at mitigating this issue. 
The absence of genetic associations with plasma I-FABP or sCD14 allows better 
interpretation of microbial translocation data and demonstrates that the previously 
identified genetic variants that are associated with HIV viral load are independent of 
sCD14. Our finding of associations between I-FABP and sCD14, and between viral 
load and sCD14 reinforces the centrality of microbial translocation in the 
pathogenesis of untreated HIV infection.  
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Figure 1: No SNPs are significantly associated with I-FABP or sCD14 plasma 
levels. 
Manhattan plots showing the distribution of the results of the two genome-wide 
association studies, of I-FABP plasma levels (panel A) and of sCD14 plasma levels 
(panel B). The horizontal axes depict the human chromosomes in linear order, the 
vertical axes show association strengths as –log10(p-values). 
 
Figure 2: I-FABP and HIV viral load at set point are independently associated 
with sCD14. 
Correlations between plasma levels of (a) I-FABP and sCD14 (p=7.1x10-16, r2=0.09) 
(b) sCD14 and HIV viral load (p=7.1x10-8, r2=0.04) and (c) I-FABP and HIV viral load 
(p=0.2, r2<0.01)






















Total N 717 686 
Male gender, N (%) 543 (75.7) 520 (75.8) 
Age, median (IQR) 33 (27-40) 34 (28-40) 
Log10 HIV VL at setpoint, mean (SD) 3.81 (0.96) 3.81 (0.96) 
CD4+ T cell count, median (IQR) 460 (390-571) 452 (390-556) 
Log10 sCD14, mean (SD) 6.23 (0.13) 6.24 (0.13) 
Log10 I-FABP2, mean (SD) 2.70 (0.61) 2.70 (0.60) 
 
 















Table 2: P-values for association with HIV viral load at set point in linear regression 
models including sex, age and the coordinates of the top 3 principal components 




Genetic variants only Genetic variants + sCD14 
rs2395029 5.40E-08 9.60E-06 6.70E-06 
rs9264942 1.30E-10 3.30E-07 5.40E-07 
CCR5delta32 0.023 0.022 0.024 
sCD14 levels 7.10E-08   1.90E-07 
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